Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

12. Investor Relations & Next Steps

Positioned for Strategic Acquisition in 2026

LPBI Group is a debt-free, founder-led organization with a mature portfolio of intellectual property assets specifically engineered for domain-aware AI in Health. The portfolio is fully documented, ready for due diligence, and purpose-built for transfer of ownership.

Current Status

LPBI Group has developed a unique and defensible combination of assets, including:

• A 9 GB private multimodal corpus and a 17-part Composition of Methods (COM) Tool Factory
• 13 Hidden Gems functioning as ready-made Small Language Models (SLMs)
• Proven performance through joint publications with Grok (xAI), demonstrating significant causal reasoning uplift in oncology and cardiovascular domains
• Strong alignment with industry priorities in oncology, immunology, cardiovascular, infectious disease, and rare diseases

Strategic Opportunity

LPBI Group’s integrated ecosystem — combining high-provenance multimodal data at scale with a comprehensive proprietary methodology framework — addresses a critical gap in the current AI landscape. As pharmaceutical companies and frontier AI laboratories scale agentic systems, the demand for trusted, causally structured, and domain-specific biomedical intelligence continues to grow.

LPBI’s assets are positioned to enable strategic partners to achieve leadership in domain-aware AI across Pharmaceutical/BioPharma, Medical/Diagnosis & Therapeutics, Life Sciences/Genomics, and BioMed/Biotech/Medtech.

Next Steps – 2026 Outreach

LPBI Group is actively seeking the right strategic partner through three parallel tracks:

• Private Equity & Strategic Investors — focused on ROI, scalability, and long-term value creation
• Pharma / Biotech Companies — focused on therapeutic area acceleration and internal AI capabilities
• Hyperscalers & Foundation Model Companies — focused on high-quality multimodal data and multi-agent infrastructure

Invitation

We welcome serious inquiries from qualified parties. A full data room, including the 28-slide deck and supporting appendices, is available upon signing a mutual non-disclosure agreement.

The time to act is now. 2026 represents a pivotal window for transferring this unique moat and unlocking its full potential in domain-aware AI in Health.

Contact

Aviva Lev-Ari, PhD, RN

Founder & Editor-in-Chief Leaders in Pharmaceutical Business Intelligence (LPBI) Group

AvivaLev-Ari@alum.Berkeley.edu